Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rivoceranib - Jiangsu Hengrui Medicine Co/Elevar Therapeutics

Drug Profile

Rivoceranib - Jiangsu Hengrui Medicine Co/Elevar Therapeutics

Alternative Names: Aitan; Apatinib; Apatinib mesylate; YN-968-D1

Latest Information Update: 17 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Advenchen Laboratories LLC
  • Developer Bukwang Pharmaceutical; Elevar Therapeutics; Fudan University Shanghai Cancer Center; Henan Cancer Hospital; Jiangsu Hengrui Medicine Co.; Peking Union Medical College Hospital; Peking University People's Hospital; Sun Yat-Sen University; The Affiliated Hospital of the Chinese Academy of Military Medical Science
  • Class Amides; Antineoplastics; Cyclopentanes; Nitriles; Pyridines; Small molecules
  • Mechanism of Action Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastric cancer
  • Phase III Fallopian tube cancer; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer
  • Phase II Breast cancer; Cholangiocarcinoma; Colorectal cancer; Lung cancer; Malignant melanoma; Osteosarcoma; Soft tissue sarcoma; Solid tumours

Most Recent Events

  • 22 Oct 2019 Jiangsu HengRui Medicine plans a phaseI/II trial for Non-small-cell Lung Cancer in China (Combination therapy, Neoadjuvant therapy) in November 2019 (NCT04133337)
  • 08 Oct 2019 LSK Biopharma plans a phase II trial for adenoid cystic carcinoma (Metastatic disease, Recurrent) (NCT04119453)
  • 29 Sep 2019 Efficacy data from the phase III ANGEL trial in Gastric cancer released by LSK BioPharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top